Aethlon Medical Inc (NASDAQ: AEMD)

Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier®, a clinical stage immunotherapeutic device designed to remove harmful extracellular vesicles and enveloped viruses from the bloodstream. The company's technology utilizes a lectin based affinity mechanism to capture pathogens and disease associated vesicles, with applications in oncology, life threatening viral infections, and organ transplantation. Aethlon Medical, Inc. has received Breakthrough Device designation from the U. S. Food and Drug Administration for two indications: treatment of advanced or metastatic cancer unresponsive to standard therapies, and treatment of life threatening viruses lacking approved therapies. The company conducts preclinical and clinical research to advance the Hemopurifier toward potential commercialization. The company's executive offices are located in San Diego, California.

Aethlon Medical, Inc. currently does not generate product revenue as the Hemopurifier remains in clinical development and has not yet received regulatory approval for commercial sale. The company's operations are financed primarily through research and development activities, which are supported by cash reserves and occasional financing arrangements. As of the most recent fiscal year, research and development expenses amounted to approximately $2,212,000, reflecting the company's focus on advancing its therapeutic platform. The company also pursues grant funding and strategic collaborations to support its research programs.

The company does not report any operating segments.

Aethlon Medical, Inc. operates in a highly competitive landscape that includes firms developing blood filtration technologies and therapeutic interventions for cancer and infectious diseases. A notable competitor mentioned in the filing is ExThera Medical Corporation, which produces blood filters targeting similar pathogen removal. The company's competitive advantages stem from its proprietary lectin based affinity technology, the Breakthrough Device designations that facilitate regulatory pathways, and its demonstrated ability to capture a broad range of enveloped viruses and extracellular vesicles in preclinical models. Additionally, Aethlon Medical, Inc. leverages its intellectual property portfolio, which includes multiple issued patents and pending applications, to protect its core technology.

The company collaborates with a variety of hospitals and research institutions to conduct its clinical trials and preclinical studies. Specific partners include Royal Adelaide Hospital, Pindara Private Hospital, GenesisCare North Shore Hospital in Australia, Medanta Medicity Hospital in India, DaVita MedCenter Dialysis in Houston, Texas, Apollo Hospital, Fortis Hospital in India, and the University of Pittsburgh in the United States. These relationships provide Aethlon Medical, Inc. with access to patient populations, clinical expertise, and trial sites necessary for advancing the Hemopurifier through developmental stages. The company does not currently sell products to end users, as its focus remains on establishing safety and efficacy data.